Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Disability evaluation under social security (hematological disorders-adult)
source: Social Security Administration
year: N/A
summary/abstract:A. What hematological disorders do we evaluate under these listings?
– We evaluate non-malignant (non-cancerous) hematological disorders, such as hemolytic anemias (107.05), disorders of thrombosis and hemostasis (107.08), and disorders of bone marrow failure (107.10). These disorders disrupt the normal development and function of white blood cells, red blood cells, platelets, and clotting-factor proteins (factors).
– We evaluate malignant (cancerous) hematological disorders, such as lymphoma, leukemia, and multiple myeloma, under the appropriate listings in 13.00, except for two lymphomas associated with human immunodeficiency virus (HIV) infection. We evaluate primary central nervous system lymphoma associated with HIV infection under 114.11B, and primary effusion lymphoma associated with HIV infection under 114.11C.
B. What evidence do we need to document that you have a hematological disorder?
We need the following evidence to document that you have a hematological disorder:
– A laboratory report of a definitive test that establishes a hematological disorder, signed by a physician; or
– A laboratory report of a definitive test that establishes a hematological disorder that is not signed by a physician and a report from a physician that states you have the disorder.
Related Content
-
Management of male fertility in sickle cell disease before and after hydroxycarbamideHydroxycarbamide (hydroxyurea or HU) is ...
-
Experimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
-
Practice variation in emergency department management of children with sickle cell disease who present with feverOBJECTIVES:Urgent medical evaluation is ...
-
Effort set to help sickle cell patients manage medsVanderbilt University Medical Center is ...
-
Bluebird bio acquires Durham, NC, manufacturing site for lentiviral vector productionbluebird bio said today it has acquired ...
-
When Cracking Down On Opioids Means Tougher Access For Sickle Cell PatientsMany people with sickle cell disease wil...
-
Patients frequently turning to cannabis to treat symptoms of sickle cell diseaseMedical cannabis use is relatively commo...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.